Last 26 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -2.97 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 118.92 | 2887.51 | 120.40 | 239.23 | 606.31 | 314.22 | 606.44 | 533.99 | 157.05 | 78.46 | 41.94 | 85.46 | 121.04 |
| — | +818.9% | -80.1% | -55.2% | +286.1% | +300.5% | +1346.0% | +524.8% | +29.7% | -31.6% | -52.0% | +2.6% | -2.5% | |
| P/B Ratio | 1.20 | 5.88 | 3.19 | 3.09 | 2.87 | 2.62 | 3.77 | 3.58 | 2.68 | 1.37 | 0.91 | 1.42 | 1.93 |
| — | +124.3% | -15.5% | -13.7% | +7.2% | +90.8% | +312.6% | +152.7% | +38.5% | -37.5% | -60.3% | -26.9% | -18.4% | |
| P/FCF | — | — | — | — | — | — | — | — | — | 11.00 | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Avidity Biosciences, Inc.'s operating margin was -29590.5% in Q4 2025, down 28077.0 pp QoQ and down 25520.8 pp YoY. The trailing four-quarter average of -10978.4% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind. Gross margin contracted 174.0% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 77.9% | -74.0% | 100.0% | -3490.5% | 100.0% | 100.0% | 100.0% | 66.4% | 81.9% | 72.0% | -1593.2% | -1742.5% | -2039.1% |
| — | -174.0% | 0.0% | -5356.2% | +22.1% | +39.0% | +106.3% | +103.8% | +104.0% | +104.7% | -13.5% | -0.9% | -41.4% | |
| Operating Margin | -3977.3% | -29590.5% | -1513.5% | -4448.7% | -8360.9% | -4069.6% | -4200.9% | -4040.4% | -2178.6% | -3043.5% | -2080.4% | -2272.6% | -2579.3% |
| — | -627.1% | +64.0% | -10.1% | -283.8% | -33.7% | -101.9% | -77.8% | +15.5% | -58.3% | -14.9% | -6.9% | -34.4% | |
| Net Margin | -3650.4% | -27569.9% | -1398.3% | -4089.3% | -7360.0% | -3439.5% | -3441.7% | -3461.8% | -1943.4% | -2756.2% | -1858.0% | -2030.4% | -2346.4% |
| — | -701.6% | +59.4% | -18.1% | -278.7% | -24.8% | -85.2% | -70.5% | +17.2% | -51.2% | -5.8% | +3.2% | -23.0% |
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -44.0% | -13.3% | -11.3% | -12.5% | -8.4% | -7.0% | -5.9% | -6.9% | -10.3% | -11.9% | -9.7% | -8.4% | -9.2% |
| — | -89.9% | -92.0% | -80.8% | +18.7% | +41.2% | +39.3% | +18.0% | -12.2% | -12.3% | +16.2% | +31.0% | -1.9% | |
| ROA | -38.9% | -11.6% | -10.0% | -11.1% | -7.7% | -6.4% | -5.4% | -6.2% | -8.7% | -10.1% | -8.8% | -7.7% | -8.4% |
| — | -81.6% | -85.1% | -80.6% | +12.1% | +36.6% | +39.2% | +19.8% | -4.2% | -6.6% | +13.6% | +29.2% | -3.7% | |
| ROIC | -42.8% | -12.8% | -11.2% | -12.6% | -8.6% | -7.7% | -8.2% | -12.1% | -16.7% | -13.0% | -10.3% | -9.1% | -12.4% |
| — | -65.7% | -35.9% | -4.1% | +48.4% | +40.8% | +20.0% | -32.8% | -34.9% | +19.5% | +23.0% | +33.1% | +23.2% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has weakened 41.5% YoY to 9.20x, tightening the short-term liquidity position. Debt/Equity has risen for 3 consecutive quarters, indicating increasing financial leverage that investors should watch closely.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.06 | 0.06 | 0.03 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 |
| — | +1073.3% | +423.9% | -37.3% | -59.2% | -75.7% | -75.3% | -59.6% | -39.1% | +6.4% | -31.6% | -46.1% | -42.9% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 9.20 | 9.20 | 11.57 | 9.26 | 16.91 | 15.73 | 17.76 | 15.78 | 12.47 | 7.58 | 11.40 | 13.14 | 12.42 |
| — | -41.5% | -34.8% | -41.3% | +35.6% | +107.7% | +55.7% | +20.1% | +0.4% | -36.9% | +17.4% | +9.5% | -5.1% | |
| Quick Ratio | 9.20 | 9.20 | 11.57 | 9.26 | 16.91 | 15.73 | 17.76 | 15.78 | 12.47 | 7.58 | 11.40 | 13.14 | 12.42 |
| — | -41.5% | -34.8% | -41.3% | +35.6% | +107.7% | +55.7% | +20.1% | +0.4% | -36.9% | +17.4% | +9.5% | -5.1% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 26 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonAvidity Biosciences, Inc.'s current P/E is -3.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Avidity Biosciences, Inc.'s current operating margin is -3977.3%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Avidity Biosciences, Inc.'s business trajectory between earnings reports.